红细胞生成素治疗兔脑血管痉挛及对核因子κB表达的影响

目的探讨红细胞生成素（EPO）对兔蛛网膜下腔出血（SAH）后迟发性脑血管痉挛（CVS）的疗效及其对核因子κB（NF-κB）表达的影响。方法取雄性新西兰白兔36只,随机分为对照组、SAH组和EPO治疗组,每组12只。采用枕大池二次注血SAH模型诱发迟发性CVS。EPO注射剂量为1000IU/kg,1次/8h;对照组和SAH组均给予EPO的溶剂（含人血清蛋白2.5mg/ml、氯化钠352mmol/L及蒸馏水）,以1ml/kg经腹腔注射,连续腹腔注射15次。造模后第5天处死动物,取基底动脉,采用HE染色测定基底动脉管腔横截面积,并用凝胶电泳迁移分析法检测NF-κB活性。结果①对照组、SAH组和EPO治疗组兔的基底动脉管腔横截面积分别为（0.412±0.034）、（0.210±0.018）和（0.342±0.030）mm2。SAH组与对照组比较,P〈0.01;EPO治疗组与SAH组比较,P〈0.01,与对照组比较,P〈0.05。②对照组、SAH组和EPO治疗组的NF-κB活性灰度值分别为：1.20±0.11、9.30±1.12和6.60±0.13,SAH组与对照组比较、EPO治疗组与对照组和SAH组比较,差异均有统计学意义（P〈0.01）。结论EPO能够缓解SAH后的迟发性CVS,并抑制SAH后血管中NF-κB的表达。

Erythropoietin for treatment cerebral vasospasm after subarachnoid hemorrhage and its effect on the expression of regulating nuclear factor kappa B in rabbits

Objective To investigate the efficacy of erythropoietin （EPO） in delayed cerebral vasospasm following subarachnoid hemorrhage （SAH） and its regulatory effect on the expression of nuclear fac- tor kappa B （NF-KB） in rabbits. Methods A total of 36 male New Zealand white rabbits were selected, and they were randomly allocated into control, SAH, and EPO groups （n = 12 in each group）. Delayed cerebral vasospasm was induced by using a SAH model of injecting autologous blood into the cisterna magna. The dose of EPO was 1000 IU/（ kg· 8 h）, and it was injected intraperitoneally for 5 days. The animals were killed 5 days after the model established. Their basilar arteries were obtained and the cross- section area was detected by HE staining. The NF-KB binding activity was detected by electrophoretic mob- ility shift assay （EMSA）. Results （1）The lumen~ cross-sectional areas of basilar arteries in the control, SAH and EPO groups were 0. 412 ±0. 034, 0. 210 ±0. 018, and 0. 342 ±0. 030 mm2, respectively. There was significant difference between the SAH and the control groups （P 〈0.01 ）, and between the EPO and the SAH groups （ P 〈0. 01 ）. There was also significant difference between the EPO and the control groups （P 〈0. 05）. （2）The gray values of NF-KB activity in the 3 groups were 1.20 ±0. 11, 9. 30± 1.12, and 6. 60± 0. 13, respectively. There were significant differences between the SAH and the control groups, and between the EPO, control and SAH groups （P 〈 0.01 ）. Conclusion EPO may relieve delayed cerebral vasospasm after SAH, and inhibit the expression of NF-KB in cerebral arteries after SAH.